Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/art.40044 http://scihub22266oqcxt.onion/10.1002/art.40044 C5378642!5378642!28133925     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28133925&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Arthritis+Rheumatol 2017 ; 69 (4): 837-45 Nephropedia Template TP {{tp|p=28133925|t=2017. A RANDOMIZED, DOUBLE-BLIND TRIAL OF ABATACEPT (CTLA4-IG) FOR THE TREATMENT OF GIANT CELL ARTERITIS |pdf=|usr=}}{{28133925}} gab.com Text A RANDOMIZED, DOUBLE-BLIND TRIAL OF ABATACEPT (CTLA4-IG) FOR THE TREATMENT OF GIANT CELL ARTERITIS JO: Arthritis Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=28133925 #FOAvip Objective: To compare the efficacy of abatacept to placebo for giant cell arteritis (GCA). Methods: In this multicenter trial, patients with newly-diagnosed or relapsing GCA were treated with abatacept 10 mg/kg IV on days 1, 15, 29, week 8, together with prednisone. At week 12, patients in remission underwent a double-blinded randomization to continue monthly abatacept or switch to placebo. Patients in both study arms received a standardized prednisone taper with discontinuation of prednisone at week 28. Patients remained on their randomized assignment until meeting criteria for early termination or until 12 months after enrollment of the last patient. The primary endpoint was duration of remission (relapse-free survival). Results: Forty-nine eligible patients with GCA were enrolled and treated with prednisone and abatacept; forty-one reached the week 12 randomization and underwent a blinded randomization to abatacept or placebo. Prednisone was tapered using a standardized schedule reaching 20 mg daily at week 12 with discontinuation in all patients at week 28. The relapse-free survival at 12 months was 48% for those receiving abatacept and 31% for those receiving placebo (p=0.049). A longer median duration of remission was seen with abatacept (9.9 months) compared to placebo (3.9 months, p=0.023). There was no difference in the frequency or severity of adverse events between treatment arms, including infection. Conclusions: In patients with GCA the addition of abatacept to a treatment regimen with prednisone reduced the risk of relapse and was not associated with a higher rate of toxicity compared to prednisone alone. Twit Text FOAVip A RANDOMIZED, DOUBLE-BLIND TRIAL OF ABATACEPT (CTLA4-IG) FOR THE TREATMENT OF GIANT CELL ARTERITIS ????Arthritis Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=28133925 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28133925 #FOAvip English Wikipedia <ref>{{Cite pmid|28133925}}</ref> A RANDOMIZED, DOUBLE-BLIND TRIAL OF ABATACEPT (CTLA4-IG) FOR THE TREATMENT OF GIANT CELL ARTERITIS #MMPMID28133925 Langford CA; Cuthbertson D; Ytterberg SR; Khalidi N; Monach PA; Carette S; Seo P; Moreland LW; Weisman M; Koening CL; Sreih A; Spiera R; McAlear CA; Warrington KJ; Pagnoux C; McKinnon K; Forbess LJ; Hoffman GS; Borchin R; Krischer JP; Merkel PA Arthritis Rheumatol 2017[Apr]; 69 (4): 837-45 PMID28133925show ga Objective: To compare the efficacy of abatacept to placebo for giant cell arteritis (GCA). Methods: In this multicenter trial, patients with newly-diagnosed or relapsing GCA were treated with abatacept 10 mg/kg IV on days 1, 15, 29, week 8, together with prednisone. At week 12, patients in remission underwent a double-blinded randomization to continue monthly abatacept or switch to placebo. Patients in both study arms received a standardized prednisone taper with discontinuation of prednisone at week 28. Patients remained on their randomized assignment until meeting criteria for early termination or until 12 months after enrollment of the last patient. The primary endpoint was duration of remission (relapse-free survival). Results: Forty-nine eligible patients with GCA were enrolled and treated with prednisone and abatacept; forty-one reached the week 12 randomization and underwent a blinded randomization to abatacept or placebo. Prednisone was tapered using a standardized schedule reaching 20 mg daily at week 12 with discontinuation in all patients at week 28. The relapse-free survival at 12 months was 48% for those receiving abatacept and 31% for those receiving placebo (p=0.049). A longer median duration of remission was seen with abatacept (9.9 months) compared to placebo (3.9 months, p=0.023). There was no difference in the frequency or severity of adverse events between treatment arms, including infection. Conclusions: In patients with GCA the addition of abatacept to a treatment regimen with prednisone reduced the risk of relapse and was not associated with a higher rate of toxicity compared to prednisone alone. äA RANDOMIZED, DOUBLE-BLIND TRIAL OF ABATACEPT (CTLA4-IG) FOR THE TREAT(epmc).pdf DeepDyve Pubget Overpricing